You need to be logged in to view this video

Biotech Investing: The Covid-19 "Delta" Variant Means the Job Is Not Done

Released on Tuesday, August 10, 2021•BIOTECH

Share
Facebook Twitter LinkedIn SMS

Biotech Covid-19 vaccine development has demonstrated the power of biotech to change the world and make handsome returns for investors. With the Delta variant wrecking devastation worldwide, join this presentation to discover what's next. Can an oral vaccine be the difference maker to finally tame Covid-19?

John McCamant

Medical Technology Stock Letter, Editor

John McCamant joined the leading investment newsletter, Medical Technology Stock Letter, as an associate editor in 1987 and was named editor in August 2000. He has spent over 35 years on the front lines of biotechnology investing. In his previous role as an equities analyst for the American Healthcare fund, Mr. McCamant uncovered investment opportunities and guided investment strategy.